Mission Bio
/ 400 E Jamie Ct, Suite 100
CA 94080 South San Francisco
US
Mission Bio
Foundation date
2012
Sector
#PharmaSubsector
- #R&D Services - Drug delivery
- #R&D Services - Genomics
- #R&D Services - Proteomics
- #Pharma - Cell therapy
- #Pharma - Drug delivery
- #Pharma - Gene therapy
Mission Bio unlocks the ground truth of cancer through response, relapse, and remission with its Tapestri Platform, powered by single-cell multi-omics. As the first and only to analyze genotype and phenotype simultaneously in single cells, the Tapestri Platform can help unravel the inherent complexity of cancer. Discover how Tapestri enables accurate characterization of your cell and gene therapy candidates for safer and more effective therapeutic strategies. We partner with pharma and biopharma companies across advanced therapy development programs to implement proven single-cell multi-omics capabilities into discovery, translational, and clinical research efforts. Learn more about our Pharma Assay Development services.
Upcoming events
All events-
1010 '24
-
0411 '24
BIO-Europe® 2024 - 30th Annual International Partnering Conference
Event by: EBD Group -
1012 '24
Next-Generation Synthetic Biology
Event by: VIB
Latest news
More news-
Kurma Partners achieves first close of new EUR 250 million Biofund IV
Thursday October 3rd 2024
Read more
-
Confo Therapeutics Announces Publication in Nature Communications Demonstrating First-Ever Structure of a Complex Between an Antibody-based Agonist and a Class A GPCR Regulating Hunger and Satiety
Tuesday October 1st 2024
Read more
-
Obulytix appoints Dr. Kristof Van Emelen as Chief Executive Officer
Tuesday October 1st 2024
Read more
Jobs
More jobsMore info?
Ellen Telleir
Communication Coordinator